ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2411

Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting

John Kelsall1, Algis Jovaisas2, Proton Rahman3, Dalton Sholter4, Michael Starr5, William Bensen6, Maqbool Sheriff7, Wojciech Olszynski8, Michel Zummer9, Rafat Faraawi10, Andrew Chow11, Suneil Kapur12, Emmanouil Rampakakis13, John S. Sampalis13, Francois Nantel14, Susan Otawa15, May Shawi14 and Allen J Lehman15, 1The Mary Pack Arthritis Centre, Vancouver, BC, Canada, 2194 Main Street, University of Ottawa, Ottawa, ON, Canada, 3Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, 4University of Alberta, Edmonton, AB, Canada, 5Rheumatology, McGill University Health Centre, Montreal, QC, Canada, 6St Josephs Hospital and McMaster University, Hamilton, ON, Canada, 7Nanaimo Regional General Hospital, Nanaimo, BC, Canada, 8University of Saskatchewan, Saskatoon, SK, Canada, 9Université de Montréal, Montreal, QC, Canada, 10Medicine, McMaster University, Hamilton, ON, Canada, 11McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, 12Rheumatology, University of Ottawa, Ottawa, ON, Canada, 13JSS Medical Research, Montreal, QC, Canada, 14Janssen Inc., Toronto, ON, Canada, 15Medical Affairs, Janssen Inc., Toronto, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: infliximab, Psoriatic arthritis, registry, rheumatoid arthritis (RA) and treatment

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Clinical Aspects (ACR): Impact of Various Interventions and Therapeutic Approaches

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. The objective of this analysis was to assess in Canadian routine clinical practice the durability of treatment with infliximab (IFX) in PsA and RA and the determinants associated with sustainability of IFX.

Methods:

BioTRAC is an ongoing, prospective registry of patients initiating treatment for RA, AS, or PsA with infliximab or golimumab as first biologics or after having been treated with a biologic for less than six months. Patients with PsA or RA treated with IFX who were enrolled between 2002 (2005 for PsA patients) and 2012 were included in this analysis. Dose optimization was defined as an increase in the frequency and/or dosing of IFX.  Kaplan Meier (KM) estimates and Cox proportional models were used in the analysis.

Results:

A total of 92 PsA and 830 RA patients were included in the analysis. Mean (SD) age of the PsA and RA patient cohorts was 48.7 (9.9) and 55.8 (13.4) years, respectively, and mean (SD) duration since diagnosis was 6.8 (9.1) and 10.2 (10.1) years, respectively. Twenty seven (29.3%) PsA patients and 407 (49.0%) RA patients had discontinued treatment. Overall KM-based mean (SE) duration of treatment was 41.4 (3.6) months and 61.3 (2.2) months for PsA and RA patients, respectively. Longer treatment duration was associated with significantly greater improvements in pain (parameter estimate PsA: -0.21, P=0.020; RA: -0.27, P<0.001), patient global (PsA: -0.35, P<0.001; RA: -0.28, P<0.001) and HAQ-DI (PsA: -0.01, P<0.001; RA: -0.01, P<0.001). Significant associations with duration of treatment in PsA patients were observed for disease duration (HR=1.04), previous biologic (HR=2.10), baseline TJC28 (HR=1.10), baseline PASI (HR=0.86) and concomitant use of traditional DMARD(s) (HR=0.16) or NSAID(s) (HR=0.38). For RA patients, IFX dose optimization (HR=0.72) and concomitant use of steroids (HR=1.78) were identified as significant predictors of treatment durability.  

Conclusion:

The results of this observational study have shown a high durability of treatment with IFX for patients with PsA or RA in a real-world setting. Concomitant medication use significantly impacts treatment durability. Furthermore, longer disease duration, higher TJC, less severe skin disease at initiation and previous biologic use in PsA, and absence of IFX dose optimization in RA, may be associated with reduced treatment durability.


Disclosure:

J. Kelsall,

Janssen Inc.,

5;

A. Jovaisas,

Janssen Inc.,

5;

P. Rahman,

Consulting fees for Abbott, AbbVie, Amgen, BMS, Celgene, Janssen, Novartis, Pfizer and Roche,

5;

D. Sholter,

Janssen Inc.,

5;

M. Starr,

Janssen Inc.,

5;

W. Bensen,

Janssen Inc,

5;

M. Sheriff,

Janssen Inc.,

5;

W. Olszynski,

Janssen Inc.,

5;

M. Zummer,

Janssen Inc.,

5;

R. Faraawi,
None;

A. Chow,

Janssen Inc.,

5;

S. Kapur,
None;

E. Rampakakis,
None;

J. S. Sampalis,
None;

F. Nantel,

Janssen Inc.,

3;

S. Otawa,

Janssen Inc.,

3;

M. Shawi,

Janssen Inc.,

3;

A. J. Lehman,

Janssen Inc.,

3.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessing-treatment-durability-of-infliximab-in-the-management-of-psoriatic-arthritis-and-rheumatoid-arthritis-patients-in-a-canadian-setting/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies